Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04308304 · ClinicalTrials.gov registry record · Phase 1
MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT04308304 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 27 participants.
The verdict
NCT04308304, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The study investigated the effects on safety and pharmacokinetics (PK) of MK-1942 and donepezil when co-administered to participants with Alzheimer's Disease with mild-to-moderate cognitive impairment stably treated with donepezil. The objectives of this study were to determine if the combination of MK-1942 with donepezil increases the incidence or severity of adverse events (AEs) previously reported for these agents alone, or results in unanticipated AEs in the patient population targeted for MK-1942 treatment. In addition, changes in the PK parameters of either MK-1942 or donepezil as a result of co-administration were assessed.
Interventions
- DRUG Placebo
- DRUG Donepezil
- DRUG MK-1942
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-02-16 |
| Est. Completion | 2022-05-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04308304
The ClinicalTrials.gov registry entry for NCT04308304 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04308304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04308304 about?
NCT04308304 is a clinical study titled "MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)". The study investigated the effects on safety and pharmacokinetics (PK) of MK-1942 and donepezil when co-administered to participants with Alzheimer's Disease with mild-to-moderate cognitive impairment stably treated with donepezil. The objectives of this study were to determine if the combination of...
What is the current status of trial NCT04308304?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2021-02-16. Estimated completion is 2022-05-18.
What interventions are being tested in trial NCT04308304?
The interventions under investigation include: Placebo (DRUG), Donepezil (DRUG), MK-1942 (DRUG).
Who is sponsoring clinical trial NCT04308304?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.